Replimune Group (NASDAQ:REPL) was upgraded by equities research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued to investors on Friday, Marketbeat reports. The firm presently has a $26.00 target price on the stock, down from their prior target price of $27.00. JPMorgan Chase & Co.‘s target price suggests a potential upside of 98.17% from the company’s previous close.

REPL has been the subject of a number of other reports. Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Wedbush cut their target price on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, April 24th. Finally, HC Wainwright set a $73.00 target price on shares of Uniqure and gave the company a “buy” rating in a report on Monday, July 8th. Six equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $24.67.

REPL stock opened at $13.12 on Friday. The firm has a fifty day simple moving average of $13.53. Replimune Group has a fifty-two week low of $8.88 and a fifty-two week high of $23.55. The company has a quick ratio of 14.26, a current ratio of 14.26 and a debt-to-equity ratio of 0.05.

A number of hedge funds and other institutional investors have recently bought and sold shares of REPL. Redmile Group LLC grew its stake in shares of Replimune Group by 1.1% in the 1st quarter. Redmile Group LLC now owns 2,212,456 shares of the company’s stock valued at $33,674,000 after purchasing an additional 23,499 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its stake in shares of Replimune Group by 13.0% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 708,120 shares of the company’s stock valued at $10,778,000 after purchasing an additional 81,642 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Replimune Group by 40.4% in the 1st quarter. Victory Capital Management Inc. now owns 177,090 shares of the company’s stock valued at $2,695,000 after purchasing an additional 50,950 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Replimune Group in the 1st quarter valued at approximately $174,000. Finally, Emerald Advisers LLC grew its stake in shares of Replimune Group by 7.1% in the 1st quarter. Emerald Advisers LLC now owns 697,898 shares of the company’s stock valued at $10,622,000 after purchasing an additional 46,428 shares during the last quarter. 59.58% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Story: Conference Calls and Individual Investors

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.